French diagnostics giant bioMérieux acquired San Diego-based Astute Medical in a $90 million cash deal announced earlier this month.
Astute developed a Federal Drug Administration-approved test for the early detection of acute kidney injuries, which are potentially fatal. The test will be added to bioMérieux’s platform to speed up the technology’s availability.
BioMérieux, with a presence in 150 countries, mainly provides diagnostic products for infectious diseases.
“BioMérieux’s global footprint, critical care presence and dedication to areas of high medical need positions the company well to advance and scale this opportunity with the Astute team and its partners,” said Chris Hibberd, Astute Medical CEO, in a news release.